HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.